top of page
Pipeline
Using its proprietary Lateral CAR platform, Leucid Bio has developed a pipeline of assets for the treatment of solid tumours and haematological malignancies.
Category
Programme
Preclinical
IND Enabling
Phase I/II
Product
Solid Tumours
LEU001
pan-ErbB
Autologous CAR T-cells
T4 (SCCHN)
LEU011
NKG2DL
Autologous CAR T-cells
γδ platform (T2)
Allogeneic CAR T-cells
Haematological
Malignancies
LEU004
Autologous CAR T-cells
γδ platform (T2)
Allogeneic CAR T-cells
bottom of page